Search Results - "Convertino, Irma"

Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline by Tuccori, Marco, Ferraro, Sara, Convertino, Irma, Cappello, Emiliano, Valdiserra, Giulia, Blandizzi, Corrado, Maggi, Fabrizio, Focosi, Daniele

“…Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such as respiratory syncytial virus pneumonia and Ebolavirus disease. In…”
Get full text

Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients by Convertino, Irma, Tuccori, Marco, Ferraro, Sara, Valdiserra, Giulia, Cappello, Emiliano, Focosi, Daniele, Blandizzi, Corrado

“…Sars-CoV-2 complications include pneumonia and acute respiratory distress syndrome (ARDS), which require intensive care unit admission. These conditions have…”
Get full text

Drug Safety and Relevant Issues in the Real-World by Barbieri, Maria Antonietta, Irrera, Natasha, Convertino, Irma

“…The global impact of the COVID-19 pandemic has underscored the pivotal role of drug safety and effective communication within the realm of pharmacovigilance,…”
Get full text

Validation of algorithms for selecting rheumatoid arthritis patients in the Tuscan healthcare administrative databases by Convertino, Irma, Cazzato, Massimiliano, Giometto, Sabrina, Gini, Rosa, Valdiserra, Giulia, Cappello, Emiliano, Ferraro, Sara, Tillati, Silvia, Bartolini, Claudia, Paoletti, Olga, Lorenzoni, Valentina, Trieste, Leopoldo, Filippi, Matteo, Turchetti, Giuseppe, Cristofano, Michele, Blandizzi, Corrado, Mosca, Marta, Lucenteforte, Ersilia, Tuccori, Marco

“…Validation of algorithms for selecting patients from healthcare administrative databases (HAD) is recommended. This PATHFINDER study section is aimed at…”
Get full text

Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies by Ferraro, Sara, Leonardi, Luca, Convertino, Irma, Blandizzi, Corrado, Tuccori, Marco

“…Inflammatory bowel diseases (IBDs) are generally not considered a risk factor for the development of lymphoma. When considering IBD treatments, there is good…”
Get full text

Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy by Convertino, Irma, Cazzato, Massimiliano, Tillati, Silvia, Giometto, Sabrina, Gini, Rosa, Valdiserra, Giulia, Cappello, Emiliano, Ferraro, Sara, Bonaso, Marco, Bartolini, Claudia, Paoletti, Olga, Lorenzoni, Valentina, Trieste, Leopoldo, Filippi, Matteo, Turchetti, Giuseppe, Cristofano, Michele, Blandizzi, Corrado, Mosca, Marta, Lucenteforte, Ersilia, Tuccori, Marco

“…Introduction: The disease activity associated with the drug-utilization patterns of biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) is poorly…”
Get full text

Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis by Convertino, Irma, Lorenzoni, Valentina, Gini, Rosa, Turchetti, Giuseppe, Fini, Elisabetta, Giometto, Sabrina, Bartolini, Claudia, Paoletti, Olga, Ferraro, Sara, Cappello, Emiliano, Valdiserra, Giulia, Bonaso, Marco, Blandizzi, Corrado, Tuccori, Marco, Lucenteforte, Ersilia

“…This study is aimed at describing tofacitinib and baricitinib users by characterizing their prescription and healthcare histories, drug and healthcare…”
Get full text

A Cross-National Comparison of Biosimilars Pricing in Argentina, Australia, Brazil, and Italy by da Silva Machado, Fernanda Lacerda, Cañás, Martín, Urtasun, Martín A, Marín, Gustavo H, Albuquerque, Flavia Caixeta, Pont, Lisa, Convertino, Irma, Bonaso, Marco, Tuccori, Marco, Kirchmayer, Ursula, Lopes, Luciane Cruz

“…Biosimilar medicines are defined as biological products highly similar to an already licensed biological product (RP). The market entry of biosimilars is…”
Get more information

Diabetes drugs and the incidence of solid cancers: a survey of the current evidence by Tuccori, Marco, Convertino, Irma, Galiulo, Maria Teresa, Marino, Alessandra, Capogrosso-Sansone, Alice, Blandizzi, Corrado

“…The evaluation of the relationship between the use of antidiabetic drug and the occurrence of cancer is extremely challenging, both from the clinical and…”
Get more information

The Impact of the COVID-19 “Infodemic” on Drug-Utilization Behaviors: Implications for Pharmacovigilance by Tuccori, Marco, Convertino, Irma, Ferraro, Sara, Cappello, Emiliano, Valdiserra, Giulia, Focosi, Daniele, Blandizzi, Corrado

“…The coronavirus disease 2019 (COVID-19) pandemic that hit the world in 2020 triggered a massive dissemination of information (an “infodemic”) about the disease…”
Get full text

Signals of Possibly Persistent Gustatory, Olfactory and Auditory Adverse Drug Reactions to Antibiotic Drugs: A Disproportionality Analysis Using the EudraVigilance Database by Ferraro, Sara, Cappello, Emiliano, Fornili, Marco, Convertino, Irma, Bonaso, Marco, Lucenteforte, Ersilia, Tuccori, Marco

Get full text

Comment on: “Deliberate Self-Poisoning: Real-Time Characterisation of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System” by Cappello, Emiliano, Valdiserra, Giulia, Bonaso, Marco, Ferraro, Sara, Convertino, Irma, Tuccori, Marco

Get full text

Olfactory and gustatory impairments in COVID‐19 patients: Role in early diagnosis and interferences by concomitant drugs by Ferraro, Sara, Tuccori, Marco, Convertino, Irma, Valdiserra, Giulia, Cappello, Emiliano, Maggi, Fabrizio, Blandizzi, Corrado, Focosi, Daniele

Get full text

Lessons learnt from the preclinical discovery and development of ensitrelvir as a COVID-19 therapeutic option by Ferraro, Sara, Convertino, Irma, Cappello, Emiliano, Valdiserra, Giulia, Bonaso, Marco, Tuccori, Marco

“…The COVID-19 pandemic stimulated the development of several therapeutic tools with several degrees of success. Ensitrelvir, a protease inhibitor that blocks…”
Get more information

An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future by Tuccori, Marco, Convertino, Irma, Ferraro, Sara, Valdiserra, Giulia, Cappello, Emiliano, Fini, Elisabetta, Focosi, Daniele

“…: In the COVID-19 pandemic emergency, research has been oriented toward the development of therapies that could cure critically ill patients and treatments…”
Get more information

Unresolved gustatory, olfactory and auditory adverse drug reactions to antibiotic drugs: a survey of spontaneous reporting to Eudravigilance by Ferraro, Sara, Convertino, Irma, Leonardi, Luca, Blandizzi, Corrado, Tuccori, Marco

“…: Sensory adverse drug reactions (ADRs) are generally expected to be transient in nature. However, spontaneous reports describe frequently these events as…”
Get more information

Comment on: "Deliberate Self‑Poisoning: Real‑Time Characterisation of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System" / Reply by Cappello, Emiliano, Valdiserra, Giulia, Bonaso, Marco, Ferraro, Sara, Convertino, Irma, Tuccori, Marco, Fusaroli, Michele, Pelletti, Guido, Giunchi, Valentina, Raschi, Emanuel, De Ponti, Fabrizio, Pelotti, Susi, Poluzzi, Elisabetta

Get full text

Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence by Convertino, Irma, Ferraro, Sara, Cappello, Emiliano, Valdiserra, Giulia, Bonaso, Marco, Tuccori, Marco

“…Direct-acting SARS-CoV-2 antiviral monoclonal antibodies have been an integral part of therapeutic strategies against COVID-19 pandemic. The monoclonal…”
Get more information

Potential missed diagnoses of Crohn's disease in tertiary care: impact on drug utilization and healthcare facilities use by Ferraro, Sara, Cappello, Emiliano, Bartolini, Claudia, Convertino, Irma, Bertani, Lorenzo, Lucenteforte, Ersilia, Costa, Francesco, Paoletti, Olga, Giometto, Sabrina, Gini, Rosa, Tuccori, Marco

“…A missed diagnosis of Crohn's disease (CD) can delay treatment initiation with consequences on disease course. To measure the possible impact of missed…”
Get full text

Potential Direct Costs of Adverse Drug Events and Possible Cost Savings Achievable by their Prevention in Tuscany, Italy: A Model-Based Analysis by Convertino, Irma, Salvadori, Stefano, Pecori, Alessandro, Galiulo, Maria Teresa, Ferraro, Sara, Parrilli, Maria, Corona, Tiberio, Turchetti, Giuseppe, Blandizzi, Corrado, Tuccori, Marco

“…Introduction Adverse drug events (ADEs) may represent an important item of expenditure for healthcare systems and their prevention could be associated with a…”
Get full text